Trump brings back the "most favored nation" initiative in a bid to lower drug prices in the U.S.

The Trump administration is reintroducing a contentious policy aimed at reducing U.S. pharmaceutical costs by aligning them with prices in other high-income countries, as detailed in an executive order issued on May 12. Trump claims this policy will significantly lower prescription drug prices. However, it is likely to face legal challenges from drug manufacturers, who argue that only Congress can legally negotiate drug prices. Critics, including industry representatives and Senator Ron Wyden, express concerns that the policy could harm drug innovation and economic investment in the U.S.